There are concerns that sodium–glucose cotransporter 2 (SGLT2) inhibitors may increase risk of bladder cancer. Such an association was indicated early in the development of the drug class and was subsequently shown in meta-analyses of randomized trials (1) and in analyses of spontaneous reports (2), although the evidence is conflicting (3). Based on animal studies, concerns have also been raised regarding an increased risk of renal cancer. Randomized trials have shown an imbalance for this cancer among patients receiving SGLT2 inhibitors versus placebo or other glucose-lowering drugs (3).
Patiëntvoorbeelden m.b.t. vergoeding
- ten laste van verzekeraar
- geen vergoeding door verzekeraar